AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma

Significant reduction found in risk for disease progression/death for C+R versus placebo and rituximab
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news